enGene Therapeutics Inc. — Net Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/614ddf9f-2b94-43b0-9476-825d9a1093ab/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-117.3M | 2024-11-01 – 2025-10-31 | evidence 0001193125-25-328743 |
| FY 2024 | $-55.1M | 2023-11-01 – 2024-10-31 | evidence 0000950170-24-138472 |
| FY 2023 | $-99.9M | 2022-11-01 – 2023-10-31 | evidence 0000950170-24-008125 |
| FY 2022 | $-24.5M | 2021-11-01 – 2022-10-31 | evidence 0000950170-24-008125 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).